A Phase 3 interventional study of Cabozantinib tablets and Everolimus (Afinitor) tablets in Renal Cell Carcinoma, sponsored by Exelixis. Completed at 205 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-27.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 3rd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
dr. Tom van der Hulle · Sites in Netherlands
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 27 · Phase 3 6 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 658 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 44 across the 42 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 42 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
10 studies in Carcinoma, Renal Cell by Exelixis: 2 open now, 6 under way, 3 of them phase 3. Of 4 finished, 1 (25%) have results posted.
Among the 10 studies in Carcinoma, Renal Cell by Exelixis, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 3, and was the 2nd registered.
Exelixis’s Carcinoma, Renal Cell studies by the year they started, since 2010.
13 of the studies testing cabozantinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05263050Fox Chase Cancer CenterTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | 2026-12 |
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT06835972Memorial Sloan Kettering Cancer CenterA Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | 2027-02 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT07187869M.D. Anderson Cancer CenterModulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | 2027-04-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, from their registry updates:
Among Exelixis’s 10 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Select Inclusion Criteria:
Select Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib (XL184) 60 mg tablet once daily.
Drug: Cabozantinib tablets
Everolimus (Afinitor) 10 mg tablet once daily.
Drug: Everolimus (Afinitor) tablets
Also known as: XL184
Progression-free Survival (PFS)
The primary analysis of PFS is the time from randomization to date of first documented tumor progression as determined by investigator (per RECIST 1.1 criteria) or death due to any cause, whichever occurred first. A Kaplan-Meier analysis was performed to estimate the median duration.
Time frame: PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.
Overall Survival (OS)
Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).
Time frame: OS was measured from the time of randomization until 320 deaths, approximately 28 months
Objective Response Rate (ORR)
Objective Response Rate (ORR) is the number of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. ORR was assessed by the Independent Radiology Committee (IRC) per RECIST 1.1 which was confirmed by a subsequent visit \>= 28 days later, and was analyzed in the Intent to Treat (ITT) population at the time of the primary analysis of Progression Free Survival (PFS). The data cutoff date was 22 May 2015.
Time frame: ORR was assessed at 8 weeks post-randomization, every 8 weeks for 12 months, and every 12 weeks until date of disease progression or death, up to May 2015 (approximately 21 months)
First patient enrolled: 08 August 2013, Data cut off date: 22 May 2015
| Milestone | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| Started | 330 | 328 |
| Completed | 132 | 73 |
| Not completed | 198 | 255 |
| Withdrew: Adverse event | 32 | 31 |
| Withdrew: Clinical deterioration | 29 | 50 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Physician decision | 5 | 2 |
| Withdrew: Withdrawal by subject | 6 | 11 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Progressive disease | 122 | 158 |
| Withdrew: Reason not provided | 0 | 1 |
| Milestone | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| Started | 187 | 188 |
| Completed | 56 | 36 |
| Not completed | 131 | 152 |
| Withdrew: Adverse event | 21 | 20 |
| Withdrew: Clinical deterioration | 18 | 29 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Withdrew: Progressive disease | 82 | 92 |
| Withdrew: Other | 0 | 1 |
The primary analysis of PFS is the time from randomization to date of first documented tumor progression as determined by investigator (per RECIST 1.1 criteria) or death due to any cause, whichever occurred first. A Kaplan-Meier analysis was performed to estimate the median duration.
| months | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| Progression-free Survival (PFS) | 7.4 (5.6 to 9.1) | 3.8 (3.7 to 5.4) |
Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).
| months | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| Overall Survival (OS) | 21.4 (18.7 to NA) | 16.5 (14.7 to 18.8) |
Objective Response Rate (ORR) is the number of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. ORR was assessed by the Independent Radiology Committee (IRC) per RECIST 1.1 which was confirmed by a subsequent visit \>= 28 days later, and was analyzed in the Intent to Treat (ITT) population at the time of the primary analysis of Progression Free Survival (PFS). The data cutoff date was 22 May 2015.
| percentage of participants | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| Objective Response Rate (ORR) | 17 | 3 |
Collected over 08 August 2013 - 22 May 2015. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib (XL184) | — | 131/331 (39.6%) | 328/331 (99.1%) |
| Everolimus (Afinitor) | — | 139/322 (43.2%) | 270/322 (83.9%) |
| Event | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| PneumoniaInfections and infestations | 6/331 | 13/322 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/331 | 13/322 |
| AnaemiaBlood and lymphatic system disorders | 6/331 | 12/322 |
| Renal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/331 | 11/322 |
| Abdominal PainGastrointestinal disorders | 10/331 | 2/322 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 10/331 | 6/322 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/331 | 8/322 |
| DehydrationMetabolism and nutrition disorders | 3/331 | 7/322 |
| DiarrhoeaGastrointestinal disorders | 7/331 | 2/322 |
| NauseaGastrointestinal disorders | 7/331 | 2/322 |
| Event | Cabozantinib (XL184) | Everolimus (Afinitor) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 245/331 | 88/322 |
| FatigueGeneral disorders | 185/331 | 149/322 |
| NauseaGastrointestinal disorders | 164/331 | 89/322 |
| Decreased AppetiteMetabolism and nutrition disorders | 152/331 | 108/322 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 139/331 | 19/322 |
| HypertensionVascular disorders | 122/331 | 23/322 |
| VomitingGastrointestinal disorders | 105/331 | 44/322 |
| Weight DecreasedInvestigations | 104/331 | 39/322 |
| ConstipationGastrointestinal disorders | 83/331 | 61/322 |
| DysgeusiaNervous system disorders | 78/331 | 30/322 |
| Age, Customized(participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| <65 | 196 | 198 | 394 |
| 65 to <75 | 107 | 94 | 201 |
| 75 to <85 | 26 | 36 | 62 |
| =>85 | 1 | 0 | 1 |
| Sex/Gender, Customized(participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| Male | 253 | 241 | 494 |
| Female | 77 | 86 | 163 |
| Missing | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 19 | 18 | 37 |
| Ethnicity — Not Hispanic or Latino | 278 | 273 | 551 |
| Ethnicity — Unknown or Not Reported | 33 | 37 | 70 |
| Race (NIH/OMB)(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 26 | 47 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 9 |
| White | 269 | 263 | 532 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 34 | 36 | 70 |
| Geographic Region(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| Europe | 167 | 153 | 320 |
| North America | 118 | 122 | 240 |
| Asia Pacific | 39 | 47 | 86 |
| Latin America | 6 | 6 | 12 |
| Randomization Stratification Factors per CRF(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| Prior VEGFR-TKI = 1 | 235 | 229 | 464 |
| Prior VEGFR-TKI ≥ 2 | 95 | 99 | 194 |
| MSKCC risk factors = 0 | 150 | 150 | 300 |
| MSKCC risk factors = 1 | 139 | 135 | 274 |
| MSKCC risk factors = 2 or 3 | 41 | 43 | 84 |
| Prior VEGFR-TKI = 1, MSKCC risk factors = 0 | 102 | 100 | 202 |
| Prior VEGFR-TKI = 1, MSKCC risk factors = 1 | 107 | 103 | 210 |
| Prior VEGFR-TKI = 1, MSKCC risk factors = 2 or 3 | 26 | 26 | 52 |
| Prior VEGFR-TKI ≥ 2, MSKCC risk factors =0 | 48 | 50 | 98 |
| Prior VEGFR-TKI ≥ 2, MSKCC risk factors = 1 | 32 | 32 | 64 |
| Prior VEGFR-TKI ≥ 2, MSKCC risk factors = 2 or 3 | 15 | 17 | 32 |
| Karnofsky performance status (KPS)(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| 100 (normal activity) | 99 | 74 | 173 |
| 90 (normal activity, minor signs and symptoms) | 127 | 142 | 269 |
| 80 (normal w/effort, minor signs/symptoms) | 75 | 90 | 165 |
| 70 (unable to work, cares for self) | 29 | 22 | 51 |
| Heng Prognostic Criteria(Participants) | Cabozantinib (XL184) | Everolimus (Afinitor) | Total |
|---|---|---|---|
| 0 adverse factors (favorable risk) | 66 | 62 | 128 |
| 1-2 adverse factors (intermediate risk) | 210 | 214 | 424 |
| 3-6 adverse factors (poor risk) | 54 | 52 | 106 |
Showing the first 100 of 205 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2013, a primary completion of May 2015 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib